Abstract 16P
Background
Ovarian cancer (OC) is the second gynecological malignancy among women and presents high rates of recurrence associated with chemoresistance. Tumor cells adjust their energy metabolism in favor of their rapid progression. Melatonin (Mel), a hormone produced and secreted by the pineal gland during darkness, has obvious anti-tumor activities. Therefore, we investigated the mechanistic role of Mel on energy metabolism in human OC cells (SKOV-3 and CAISMOV24 cells), with special focus on glycolytic metabolism in addition to cell signaling molecules.
Methods
Cell lines were treated with Mel at concentrations of 3.4 μM for SKOV-3 and 7 μM for CAISMOV24 based on the cell cytotoxicity (CC50) for 24 h; a luzindole-treated group was used to test the influence of melatonin receptors, MT1 and MT2. Protein levels of glycolytic enzymes were analyzed by western blot and kinase levels were measured by multiplex assay.
Results
Melatonin levels dropped by half in the OC cells. We observed a significant decline in the levels of HIF-1α, G6PDH, GAPDH, LDH, and PDH in OC cells treated with melatonin regardless of the presence of luzindole, thus proving its receptor-independent actions; conversely, the luzindole-exposed groups had an upregulation of these proteins. In regard to kinases signaling, SKOV-3 cells treated with melatonin had a reduction in the concentration of CREB, JNK, NF-kB, p-38, ERK1/2, Akt, p70s6k, STAT3, and STAT5, all of them associated with tumor growth, metastasis, and recruitment of oncostatic components. In the CAISMOV24 cells, these molecules were reduced after the combination of melatonin with luzindole.
Conclusions
These findings showed that melatonin potentially regulates energy-related processes in OC cells, thereby favoring the reversal of the Warburg effect, in addition to attenuating cell signaling involved with tumor progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute of Biosciences of Botucatu.
Funding
CAPES, FAPESP (grant number: 2021/12971-7), CNPq (304108/2020-0).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
86P - Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials
Presenter: Noé Herbel
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Clinical features and genetic profile of MDM2-altered solid tumors
Presenter: Julia Tejerina-Peces
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluation of trending drug targets and technologies in current drug development
Presenter: Matteo Repetto
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Impact of metformin on glucocorticoid-induced changes in systemic metabolism in patients with brain metastases from solid malignancies
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Effect of age on safety and efficacy of novel cancer drugs investigated in early phase clinical trials
Presenter: Jacopo Uliano
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - Molecular predictors of response to the therapy with mitotane in adrenocortical cancer
Presenter: Erika Porubayeva
Session: Cocktail & Poster Display session
Resources:
Abstract
93P - Circulating cell-free DNA fragmentation profiles during systemic therapy of advanced-stage non-small cell lung cancer patients
Presenter: Jelena Milovanovic
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Targeted therapy in pediatric acute myeloid leukemia: An unmet need
Presenter: Banda Teja
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Anticancer activity of Inula recemosa root extract in human liver cancer cell line by attenuation of OCT4/Sox2 axis
Presenter: Tania Ghosh(Sarkar)
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - The Hammersmith score optimises patient selection and predicts for overall survival in early-phase cancer trial participants independent of tumour burden
Presenter: James Korolewicz
Session: Cocktail & Poster Display session
Resources:
Abstract